You are here

Precision Medicine

We are focused on Precision Medicine as an approach to discovering and developing medicines and vaccines that deliver superior outcomes for patients, by integrating clinical and molecular information to better understand the biological basis of disease and the molecular pharmacology of our drugs. This effort leads to better selection of disease targets, and identification of patient sub-populations that demonstrate improved clinical outcomes through more tailored drugs.

We are interested in establishing alliances to develop and access:

  • Patient cohorts with high quality longitudinal clinical (e.g. electronic medical record), molecular and other phenotypic data preferably paired with broadly/appropriately consented biospecimens (e.g. whole blood serum/plasma, PBMCs, stool, etc.), and with the potential for patient recall.
  • Systems Biology/Pharmacology

    • Databases with high quality treatment and disease outcomes associated with genetic, as well as molecular (metabolomic, proteomic, transcriptomic, epigenetic, clinical chemistry markers) or functional measures, in particular with associated imaging data
    • Databases of searchable eQTLs, pQTLs across tissues
    • Disease biology guided combination therapy design platforms
    • Systems biology approaches and proven in silico tools to evaluate pharmacological perturbation and to elucidate mechanisms of in vivo toxicity
    • Mining of data for correlation and understanding of causality
  • Breakthrough diagnostic technologies that are highly quantitative, require minimal specimen/ tissue, offer quick turnaround time and can be multiplexed. This will include but not limited to:

    • Near-patient Point-of-Care technologies
    • Next Generation Sequencing technologies
    • Circulating cells
    • Circulating and urinary cell-free nucleic acids
    • Antigen receptor sequencing
    • Microbiome, including virome characterization
    • The above will ideally need to be paired with capabilities and footprint for distribution in global markets, regulatory and reimbursement strategies, and commercialization capabilities
  • In vivo imaging technologies (including MRI, PET, CT, optical imaging technologies, imaging agents, genetically encoded tags, etc.) with particular interest in

    • Imaging agents for small and large molecule compound distribution studies
    • Imaging agents monitoring physiology mechanisms and disease
    • Analytical tools and technologies
  • Biospecimen Analysis

    • Circulating tumor cell and cell free Nucleic Acid quantification and analysis
    • High dimensional single cell analysis platforms Automated IHC for tissue analysis (cancer, safety)
    • Advanced ADME-related genotyping
    • 3D cell models for safety and efficacy assessment that ideally incorporate genetic diversity
  • Physiological Biomarkers

    • Technologies adding precision to pain management and treatment in pre-clinical clinical studies
    • EEG-based biomarker for assessment of central pharmacology
  • iPS cell resources and technologies to generate iPS cells that may be used to enable Precision Medicine strategies

    • Validated cell differentiation protocols
    • iPS cells derived from sub populations with specific genotypic/phenotypic data
    • Technology to create iPS cells in a rapid and reproducible fashion without insertional approaches
  • Biospecimen collection/stabilization technologies

    • Novel sample collection approaches that allow frequent (at home) sample collection with appropriate stabilization
  • Remote Patient monitoring technologies

    • Novel actigraphy and other home monitoring systems that allow frequent at home monitoring of relevant physiological states/biomarkers
  • Advanced computational biology approaches/platforms:

    • integration of high-dimensional data across various platforms in combination with classical clinical readouts for the predictive modeling of patient response/disease progression